Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Added to the Russell Microcap Index
SAN DIEGO , June 26, 2017 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that is has been added to the Russell Microcap®
View HTML
Toggle Summary Biocept and MediNcrease Health Plans Announce Provider Agreement Expanding Access to Liquid Biopsy Testing
SAN DIEGO and ST. PETERSBURG, Fla. , June 21, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, and MediNcrease Health Plans, LLC
View HTML
Toggle Summary Biocept Awarded U.S. Patent with Broad Claims for Antibody Capture of Targets of Interest on Any Solid Surface Including CTCs and Other Materials Shed by Solid Tumors into Blood
Company's intellectual property portfolio now features 20 issued patents protecting its proprietary liquid biopsy platform technology
View HTML
Toggle Summary Biocept's Target Selector Platform Featured in Three Clinical Abstracts at the 2017 American Society of Clinical Oncology Annual Meeting Where Company Plans to Launch New Marketing Campaign
Abstracts feature clinical results demonstrating the high sensitivity of Biocept's Target Selector™ platform and the ability to identify mutations that may be missed by tissue biopsyClinical experience study evaluating 2,000 patient samples using Biocept's liquid biopsy tests shows detection of clinically actionable lung cancer mutations consistent with published prevalence rates"AND" marketing campaign highlights the benefits of using both liquid biopsy and tissue biopsy to improve the chances of rapidly identifying clinically actionable biomarkers in cancer patients
View HTML
Toggle Summary Biocept Reports First Quarter 2017 Financial Results
- Billable test volume in first quarter 2017 increases 38% over prior-year period- Revenue of $1.68 million includes impact of conversion to accrual-based revenue recognition- Enters into commercial collaborations with two major oncology treatment centers- Signs agreement to provide liquid biopsy testing in landmark clinical trial with ALCMI- Strengthens balance sheet supporting sales force expansion intended to accelerate growth- Company to host conference call at 4:30 p.m. Eastern time today
View HTML
Toggle Summary The Addario Lung Cancer Medical Institute and Biocept Announce Collaboration and Initiation of Landmark ALCMI-009 Liquid Biopsy Clinical Trial in Lung Cancer
Large prospective multi-center clinical trial designed to evaluate the impact of cancer biomarker detection and serial monitoring using liquid biopsy to improve the outcomes of patients with lung cancerPatient-founded research consortium of 25 global oncology centers to create large, well-annotated, uniformly collected biorepository of lung cancer patient blood samples
View HTML
Toggle Summary Biocept to Release First Quarter 2017 Financial Results and Host Investor Conference Call on May 11, 2017
SAN DIEGO , May 3, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it will release financial results for the
View HTML
Toggle Summary Biocept Awarded Additional Patent in Japan Expanding Intellectual Property Estate to 19 Issued Patents Protecting Its Target Selector™ Liquid Biopsy Platform
New patent provides broad coverage for the use of antibodies to capture targets of interest, including circulating tumor cells (CTCs) and other materials shed by solid tumors into the blood stream
View HTML
Toggle Summary Biocept Announces Collaboration with the OHSU Knight Cancer Institute to Increase Clinical Adoption of Liquid Biopsy Testing and to Co-Develop Additional Assay Platform Capabilities
NCI-designated cancer institute with leading molecular pathology lab obtains rights to utilize and commercially offer Biocept's Target Selector™ liquid biopsy services throughout the state of OregonKnight Diagnostic Laboratories to work with Biocept to co-develop highly sensitive, multiplexed assay panels leveraging OHSU's next generation sequencing (NGS) expertise
View HTML
Toggle Summary Biocept to Present at The MicroCap Conference on April 4th in New York City
SAN DIEGO , March 31, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
View HTML